Association of Body Mass Index and Body Composition with Survival in Metastatic Renal Cancer Patient Received Immunotherapy: A Multicenter, Retrospective Study
Jun Wang,Pei Dong,Yuanyuan Qu,Wen-Hao Xu,Zhaohui Zhou,Kang Ning,Yulu Peng,Longbin Xiong,Zhen Li,Xiangpeng Zou,Zhenhua Liu,Mingzhao Li,Zhisong He,Junhang Luo,Xi Tian,Hailiang Zhang,Shengjie Guo,Hui Han,Fangjian Zhou,Dingwei Ye,Chunping Yu,Zhiling Zhang
DOI: https://doi.org/10.2139/ssrn.4111084
2022-01-01
SSRN Electronic Journal
Abstract:Background: Obesity, defined as body mass index (BMI) ≥ 30 kg/m2, appears to be associated with better response to immunotherapy. However, BMI fails to accurately reflect body composition and the association of body composition with immunotherapy outcomes remains unclear.Methods: In this multicenter, retrospective study, we reviewed 251 metastatic renal cell carcinoma (mRCC) patients who received anti-PD1 from five centers. We analyzed the relationship between BMI, skeletal muscle area (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), subcutaneous adipose percentage (SAT%) with progression-free survival (PFS) and overall survival (OS) were analyzed. The spatial localization T cells was investigated by multiplex immunofluorescence.Findings: Among 224 evaluable patients, 23 (10.3%) patients were underweight, 118 (52.7%) had normal weight, 65 (29%) were overweight, 18 patients (8%) were obese. The median age was 55 years and most patients were male (71%). No significant improvement in PFS (HR, 0.61;95% CI, 0.27-1.42) or OS (HR, 1.09; 95% CI, 0.38-3.13) was observed for the obese patients. Besides, SM, VAT and SAT were not associated with survival outcomes (All p >0.05). Interestingly, SAT% independently predicted PFS (as continuous variable, HR: 0.02; 95% CI, 0.01-0.11) and OS (HR:0.05; 95% CI, 0.01-0.39), which remained significant in multivariate modelling (adjusted HR for PFS, 0.32; 95% CI, 0.22-0.47; adjusted HR for OS, 0.48; 95% CI, 0.29-0.80). These associations were consistent in subgroup analysis of different gender, BMI, PD-L1 positive and sarcopenia group. Tumor of high SAT% patients had a higher intratumoral PD1+ CD8+ T cells density and ratio.Interpretation: High SAT% predicts better outcomes in mRCC patients treated with anti-PD1 and its impact on T cells location and function may account for the better response.Funding Information: This study was supported by the National Natural Science Foundation of China (No. 81972382 and 81872091) and the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (No. 2021B1515020077).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: This study has been approved by the institutional review board (IRB) and the ethical committee of Sun Yat-sen University Cancer Center and was conducted in accordance with ethical principles for medical research involving human subjects reported in the Declaration of Helsinki and its later amendments. The written patient informed consent was obtained from each participating center and for some cases waiver of consent was been approved by the IRB at the corresponding center.